GlassScriptPhysician profile
Jill Adele Veverka
NPI 1245272582
$3,759.59
in general payments reported to CMS, 2019-2025
28 companies · $39.87 in 2025
The $39.87 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $978 · 2023: $1,387 · 2024: $986 · 2025: $39.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.43 |
| Education | $205.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.02 | 2021-2025 | |
| Janssen Biotech, INC. | $823.50 | 2021-2024 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.33 | 2021-2024 | Xifaxan, Plenvu |
| Qol Medical, LLC | $232.41 | 2021-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $195.86 | 2021-2024 | Entyvio |
| Daiichi Sankyo INC. | $135.07 | 2021-2024 | Injectafer |
| Intercept Pharmaceuticals, INC. | $133.37 | 2021-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $110.72 | 2024 | Iqirvo, Bylvay |
| Evoke Pharma, INC. | $91.29 | 2021-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $83.64 | 2022-2024 | Dificid |
| Pfizer INC. | $80.70 | 2022-2024 | |
| Sandoz INC. | $78.52 | 2023-2024 | Hyrimoz |
| Braintree Laboratories, INC. | $76.54 | 2022-2023 | Sutab, Suflave |
| Celgene Corporation | $73.48 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $62.39 | 2023-2025 | Yuflyma, Vegzelma |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $44.34 | 2023 | |
| Aimmune Therapeutics, INC. | $36.06 | 2023-2024 | |
| Redhill Biopharma INC. | $35.65 | 2021 | |
| Ethicon US, LLC | $34.86 | 2022 | |
| Organon LLC | $33.96 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $33.78 | 2023-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $24.13 | 2022 | |
| Ardelyx, INC. | $19.22 | 2024 | Ibsrela |
| Fresenius Kabi USA, LLC | $16.73 | 2023 | |
| Amgen INC. | $16.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.75 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.37 | 2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Veverka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.